		ANTIE	BACTERIAL ACTI	VITY				
		Zone of inbib, mm———————————————————						
Compd	Solvent	M.smegmatis	S. aureus	γ Strep.	E. coli	P. vulgaris	Ps. aeruginoso	
III	EtOH	$25^{b} (35)^{c}$						
III	$H_2O$	17(25)						
VIII	EtOH	25(33)	20	24				
IX	$H_2O$							
Х	EtOH	42(54)	19	20	18(22)	19	19	
XI	$H_2O$	15(21)	20					
XII	$EtOH^{a}$							
XIII	$H_2O$	36(69)					15	
XIV	EtOH	18	17				15	
$\mathbf{XV}$	$H_2O$	19	18					
XVI-XVIII	EtOH <sup>a</sup>							

TABLE I

" Suspension. " Complete inhibition. " Complete and partial inhibition.

greater odor than the other derivatives and gave qualitative P and S tests.

Synthesis.—The products were prepared using previously described methods<sup>2,7</sup> whereby II,<sup>6</sup> VI,<sup>16</sup> or VII<sup>16</sup> and the appropriate amine, alcohol, hydrazine, or hydrazide were treated to yield VIII (C<sub>11</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub>PS, 125°, 66%), IX (C<sub>8</sub>H<sub>18</sub>N<sub>3</sub>O<sub>5</sub>PS, 81°, 49%), X (C<sub>11</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub>PS, 147°, 38%), XI (C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O<sub>6</sub>PS<sub>2</sub>, >80°, 53%, deliquescent), XII (C<sub>8</sub>H<sub>15</sub>N<sub>4</sub>O<sub>2</sub>PS<sub>2</sub>, >115°, 76%), XIII (C<sub>16</sub>H<sub>19</sub>N<sub>8</sub>O<sub>4</sub>PS<sub>2</sub>, >105°, 94%), XV (C<sub>12</sub>H<sub>24</sub>N<sub>9</sub>O<sub>7</sub>PS<sub>3</sub>, >53°, 14°¢, deliquescent), XVI (C<sub>15</sub>H<sub>27</sub>N<sub>6</sub>O<sub>4</sub>PS<sub>6</sub>, >91%), XVII (C<sub>16</sub>H<sub>12</sub>N<sub>6</sub>O<sub>5</sub>PS<sub>4</sub>, >130°, 84%), and XVIII (C<sub>9</sub>H<sub>15</sub>N<sub>6</sub>PS<sub>4</sub>, >175°, 28%). Ether was the solvent, except in the case of XIII (CH<sub>3</sub>CN), XVI and XVII (CH<sub>3</sub>CN–ether, 1:1), and X (no solvent). Addition of II to hydrazine or 4-methyl-3-thiosemicarbazide (CH<sub>3</sub>CN) gave III (C<sub>5</sub>H<sub>12</sub>NO<sub>3</sub>PS, 129°, 61%). Consecutive additions of ethanethiol and aziridine to IV (ether) produced V (C<sub>6</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>PS<sub>2</sub>, >147°, 57%). Similar addition of phenylhydrazine and ethyl carbazate to IV (ether) yielded XIV (C<sub>15</sub>H<sub>21</sub>N<sub>6</sub>O<sub>4</sub>PS<sub>2</sub>, >65°, 25%) which separated as an oil before solidifying. One mixture (XI) was heated (35°, 1 hr) to ensure complete reaction.

Antibacterial Screening.—The antibacterial spectra were determined by saturating filter paper disks (12.7 mm) with 2 drops of an aqueous or alcoholic solution or suspension of the compound (20 mg/ml) and placing these on agar (Bacto Nutrient Agar, Difco Lab.) seeded with 48-hr culture broths (Nutrient Broth, Baltimore Biological Lab.) of the test organisms (0.5 ml). The microbial spectrum consisted of Mycobacterium smegmatis, Escherichia coli, Proteus vulgaris, Staphylococcus aureus, a  $\gamma$ Streptococcus, and Pseudomonas aeruginosa from the collections maintained at the Biology Department, University of Houston. V did not dissolve or suspend well in either solvent and was not tested. Alcohol controls were also run. The zones of inhibition around the disks were measured after 4 days of incubation (37°).

The MIC of VIII, X, XIII, INH, and alcohol against M. smegmatis and XIII and INH against M. tuberculosis<sup>17</sup> were determined by a serial broth dilution method similar to that employed by Glasser and Doughty.<sup>18</sup> The tubes, containing concentrations of 1000 to 1  $\mu$ g/ml, were examined for bacterial growth after incubation periods (37°) of 7 (M. smegmatis) and 10 days (M. tuberculosis).

Acknowledgments.—The author wishes to thank the following faculty and staff members of the University of Houston: Dr. M. R. Willcott for recording the nmr spectra, Dr. J. E. Evans and Mr. Harlan Brown for suggestions concerning the microbiological work, and Mr. N. O. Walker for preparing two starting materials and conducting some of the elemental analyses.

# Some Aza Analogs of Amino Acids<sup>1</sup>

TOMMY J. MCCORD, LLEWELLYN D. BOOTH, AND ALVIE L. DAVIS

Department of Chemistry, Abilene Christian College, Abilene, Texas

Received A pril 5, 1968

In previous work, we described the preparation of 4-azaleucine (2-amino-3-dimethylaminopropionic acid) and its potent microbiological activities as a specific and competitive antagonist of leucine.<sup>2</sup> More recently, a compound identified as 2-amino-3-dimethylaminopropionic acid by structural studies was reported to have been isolated from culture media of a certain *Streptomyces* strain.<sup>3</sup> In view of the uniqueness of 4-azaleucine as a natural product and our particular interest in aza analogs of amino acids,<sup>4,5</sup> we undertook the synthesis of 4-azanorleucine, 5-azanorleucine, and 4azanorvaline in order to determine their microbiological properties.

5-Azanorleucine was prepared in relatively poor over-all yield via an acetamidomalonic ester synthesis. Ethyl acetamidomalonate was condensed with Nbenzyl-N-methyl-2-chloroethylamine in the presence of sodium ethoxide to form ethyl 2-acetamido-2-(Nbenzyl-N-methyl-2-ethylamino)malonate. Acid hydrolysis of the condensation product gave the corresponding intermediate amino acid, 2-amino-4-(Nbenzylmethylamino)butyric acid. Subsequent hydrogenolysis of the latter compound resulted in the formation of 5-azanorleucine.

The synthesis of 4-azanorleucine and 4-azanorvaline was accomplished by using the same general procedure in which the appropriately substituted amine underwent addition with 2-acetamidoacrylic acid to yield the

<sup>(15)</sup> B. C. Saunders, J. J. Stacey, F. Wild, and I. G. E. Wilding, J. Chem. Soc., 699 (1948).

<sup>(16)</sup> B. S. Green, D. B. Sowerby, and K. J. Wilksne, *Chem. Ind.* (London), 1306 (1960).

<sup>(17)</sup> Obtained from Jefferson Davis Hospital, Tuberculosis Laboratory, Houston, Texas, through the courtesy of Mr. Henry Gonzales.

<sup>(18)</sup> A. C. Glasser and R. M. Doughty, J. Pharm. Sci., 51, 1031 (1962).

<sup>(1)</sup> The support of this work in part by Grant R-085 from the Robert A. Welch Foundation of Houston, Texas, and by Public Health Service Research Grant No. AM-4060-08 from the National Institute of Arthritis and Metabolic Diseases is gratefully acknowledged.

<sup>(2)</sup> S. S. Smith, N. L. Bayliss, and T. J. McCord, Arch. Biochem. Biophys., 102, 313 (1963).

<sup>(3)</sup> A. D. Argoudelis, R. R. Herr, D. J. Mason, T. P. Pyke, and J. F. Zieserl, Biochemistry, 6, 165 (1967).

<sup>(4)</sup> T. J. McCord, D. E. Cook, and L. G. Smith, Arch. Biochem. Biophys., 105, 349 (1964).

<sup>(5)</sup> T. J. McCord, D. C. Foyt, J. L. Kirkpatrick, and A. L. Davis, J. Med. Chem., 10, 353 (1967).

TABLE 1

Physical Constants, Yields, and Analytical Data of Aming Acid Analogs

Compd	Yield," %	$Mp_{1}^{\alpha \circ \circ}C$	Ry <sup>A</sup>	Formula
5-Azanorlencine+211Cl	72	200-201	0.085 (A), 0.34 (B), 0.33 (C)	$\mathrm{C_5H_{12}N_2O_2}$ · 2HCl
4-Azanorlencine+2HCl	75	175 - 177	0.44 (A), 0.64 (B), 0.48 (C)	$\mathrm{C_5H_{52}N_2O_2} \cdot 2\mathrm{HCl}$
4-Azanorvaline+211Cl	63	181-183	0.40 (A), 0.52 (B), 0.48 (C)	$\mathrm{C_4H_{10}N_2O_2\cdot 2HCl}$

" Melting points and yields are for analytical samples. \* The  $R_i$  values given for the appropriate solvents are indicated by letter: A, *n*-BnOH-AcOH-H<sub>2</sub>O (4:1:1); B, 65% pyridine; C, 95% MeOH. \* All compounds were analyzed for C, H, N.

corresponding 2-acetamido-3-alkylaminopropionic acid. followed by mild acid hydrolysis.

**Biological Results.**—Using *Escherichia coli* 9723 as the test organism. 5-azanorleucine, 4-azanorleucine, and 4-azanorvaline did not exert any observable inhibitory activity even at a concentration level of 2 mg·ml.

#### Experimental Section<sup>\*</sup>

Ethyl 2-Acetamido-2-(N-benzyl-N-methyl-2-ethylamino)malonate.--To a solution of 21.7 g of ethyl acetamidomalonate in 100 ml of Mg-dried EtOH containing 2.3 g of Na was added 18.3 g of freshly distilled N-benzyl-N-methyl-2-chloroethylamine<sup>7</sup> in small increments, and the reaction mixture was heated at reflux for 20 hr. The salt was removed by filtration, and the filtrate was taken to dryness *in vacuo*. Recrystallization of the residue (EtOH-H<sub>2</sub>D) gave 5.0 g  $(14^{\circ}i)$  of product, mp 34-36°. *Anal.* (C<sub>15</sub>H<sub>28</sub>N<sub>2</sub>O<sub>b</sub>) C, H.

5-Azanorvaline (2-Amino-4-methylaminobutyric Acid) Dihydrochloride.—A sample of 4.0 g of ethyl 2-acetamido-2-(Nbenzyl-N-methyl-2-ethylamino)malonate was hydrolyzed in the presence of 40 ml of 6 N HCl for 2 hr. The hydrolysis reaction mixture was taken to dryness nuder reduced pressure with warming. The resulting oil was freed of residual HCl by the repeated addition and evaporation of EtOH and the remaining residue was recrystallized (EtOH-Et<sub>2</sub>O) to yield 2.1 g (65%) of product. The extreme hygroscopic nature of the sample was such that a melting point could not readily be determined and an acceptable analysis was not obtained. The material gave a positive test with minhydrin, and the  $R_i$  values of this crude reaction product in n-BnOH-AcOH-H<sub>2</sub>O (4:1:1), 65% pyridine, and 95% MeOH were 0.37, 0.80, and 0.63, respectively.

A sample of 0.40 g of the hygroscopic 2-amino-4-(N-benzylmethylamino)butyric acid in 50% MeOH-H<sub>2</sub>O was agitated in the presence of 50 mg of Pd black under about 3.52 kg/cm<sup>2</sup> pressure of H<sub>2</sub> for 3 hr. The catalyst was removed by filtration and the filtrate was acidified to a pH 1 by addition of concentrated HCl. After the resulting solution was reduced to dryness *in racuo*, the residue was recrystallized from absolute EtOH-Et<sub>2</sub>O to yield 0.20 g of product (see Table I).

**2-Acetamido-3-ethylaminopropionic Acid.**—The synthesis of this compound was patterned after a previously described procedure for the general preparation of 3-anino-substituted derivatives of acetamidopropionic acid.<sup>5</sup> A mixture of 3.2 g of acetamidoacrylic acid and 50 ml of 33% aqueous EtNH<sub>2</sub> was allowed to stand at 40° for 72 hr. The reaction mixture was taken to dryness *in vacuo*, and the solid residue was recrystallized from absolute EtOH to yield 2.7 g (57%) of the product, mp 160–161°. Anat. (C<sub>7</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>·H<sub>2</sub>O) C, 11.

**4-Azanorleucine** (**2-Amino-3-ethylaminopropionic Acid**) Dihydrochloride.—A solution of 1.0 g of 2-acetamido-3-ethylaminopropionie acid in 20 ml of 6 N HCl was heated under reflux for 4 hr. The reaction mixture was concentrated by removal of the acid under reduced pressure and absolute EtOH was then added. After chilling in the refrigerator, 0.80 g of product was obtained (see Table 1).

2-Acetamido-3-methylaminopropionic Acid.—Using the general

(7) J. B. Wright, E. H. Lincoln, R. V. Heinzelmann, and J. H. Hunter, J. Am. Chem. Soc., 72, 3546 (1950).

(8) I. Z. Eiger and J. P. Greenstein, Nucl. Biophys., Biophys., 19, 467 (948). method<sup>8</sup> from 3.6 g of 2-acetamidoacrylic acid there was recovered 2.7 g (60%) of product, mp 164–165°, lit.<sup>8</sup> mp 164°.

**4-Azanorvaline** (2-Amino-3-methylaminopropionic Acid) Dihydrochloride.—2-Acetamido-3-methylaminopropionic acid (1 g)in 20 ml of 6 N HCl was heated at reflux for 4 hr. There was recovered 0.75 g of product from the hydrolysis reaction mixture after facilitating crystallization by the addition of absolute EtOH (see Table I).

**Microbiological Assays.**—A previously described inorganic salts–ghreese medium<sup>9</sup> was used for *E. coli* 9723, and experimental detail has been reported elsewhere.<sup>90</sup>

The amino acid analogs were dissolved in sterile  $1I_2O$  and added aseptically to the previously antoclaved assay thes. In all assays the amount of growth was determined photometrically at 625 mµ with a Bansch and Lomb Spectronic 20 spectrophotometer, in terms of absorbance readings of the turbid culture medium against a blank of uninoculated medium set at zero absorbance.

(W) E. H. Amlerson, Proc. Notl. Actob. Sci. U. S., 32, (20) (1946).
(10) D. T. H. Dien, J. M. Ravel, and W. Shive, Arch. Biochem. Biophys., 49, 283 (1954).

# Grignard Addition to

## $17\alpha$ -Acetoxy- $6\alpha$ -methylprogesterone

Abvin P. Shroff

Division of Organic Chemistry, Ortho Research Foundation, Rartitan, New Jersey - 08869

### Received May 17, 1968

Grignard addition to a steroid  $\alpha.\beta$ -unsaturated ketone has been reported by Musgrave<sup>1</sup> in 1951. He carried out 1,2 addition on cholestenone with methylmagnesium bromide to give 3-methylcholest-4-en-3-ol. A number of other investigators<sup>2-4</sup> have used cuprous chloride and cuprous acetate along with the Grignard reagent to obtain 1,4 addition. We wish to report in this communication a one-step 1,2 addition of methylmagnesium bromide to the  $\alpha.\beta$ -unsaturated ketone, 17 $\alpha$ -acetoxyto $\alpha$ -methylprogesterone (1).

An attempt to add a stoichiometric amount of methylmagnesium bromide to **1** at room temperature gave only precipitates owing to complex formation. Varying the proportious of reactants and the temperature of the reaction gave mixtures of products. However, the use of a large excess of Grignard reagent at room temperature gave  $3\xi,17\alpha$ -dihydroxy- $3\xi,6\alpha$ dimethylpregu-4-en-20-one 17-acetate (**2**) if acid was avoided in isolating the desired product. If acetic acid or dilute HCl was added in the work-up of the reaction, then dehydration occurred and  $17\alpha$ -acetoxy-3,6-dimethylpregn-3.5-dien-20-one (**3**) was isolated. When

- 13) Hiroum Mori, Chem. Phorm. Bull. (Tokyo), 12, 1224 (1064).
- (4) Bohomit Peles, Czechoslovakian Patent 111,047 (1964).

<sup>(6)</sup> All melting points are corrected. The microanalyses were performed by International Chemical and Nuclear Corp., City of Industry, Calif. All  $R_t$  data were determined using the ascending technique of paper chromatography in the solvents indicated, and ninhydrin reagent was used for the devidopment of the spors. Where analyses are indicated only by symbols of the elements, analytical results of lained by those elements were within  $\pm 0.4\%$  of the theoretical values.

<sup>(1)</sup> O. C. Musgrave, J. Chem. Soc., 3121 (1951).

<sup>(2)</sup> Merck and Co., Inc., British Patent 877,087 (1061).